Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL-1 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06869473
What this trial is testing

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Gruppo Oncologico del Nord-Ovest 67
Early research (Phase 1)Looking for participantsNCT05410717
What this trial is testing

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
Stage IV Ovarian CancerTestis Cancer, RefractoryEndometrial Cancer Recurrent+1 more
Second Affiliated Hospital of Guangzhou Medical University 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153965
What this trial is testing

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer (TNBC)PD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)Looking for participantsNCT05751798
What this trial is testing

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Solid Advanced TumorLymphomaNSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics 41
Large-scale testing (Phase 3)Study completedNCT03302234
What this trial is testing

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 568
Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Testing effectiveness (Phase 2)UnknownNCT05534113
What this trial is testing

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University 38
Large-scale testing (Phase 3)Active Not RecruitingNCT05499390
What this trial is testing

AK112 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small-cell Lung Cancer
Akeso 398
Large-scale testing (Phase 3)Study completedNCT04676412
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 107
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Large-scale testing (Phase 3)Study completedNCT05600309
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 94
Testing effectiveness (Phase 2)Ended earlyNCT03382899
What this trial is testing

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 101
Early research (Phase 1)Looking for participantsNCT06084286
What this trial is testing

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan University 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931
What this trial is testing

Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Who this might be right for
NSCLC
Shanghai Chest Hospital 35
Early research (Phase 1)Ended earlyNCT03746704
What this trial is testing

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Who this might be right for
Advanced PD-L1 Positive Malignancies
Regeneron Pharmaceuticals 2
Not applicableLooking for participantsNCT07038928
What this trial is testing

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Who this might be right for
Bladder Cancer
AstraZeneca 600
Large-scale testing (Phase 3)Looking for participantsNCT07111832
What this trial is testing

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Who this might be right for
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 400
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Who this might be right for
Breast Cancer
AstraZeneca 625
Large-scale testing (Phase 3)Active Not RecruitingNCT06635824
What this trial is testing

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Who this might be right for
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab 191
Testing effectiveness (Phase 2)Looking for participantsNCT06492759
What this trial is testing

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Emory University 29
Next Page